Universal Beteiligungs und Servicegesellschaft mbH Sells 60,082 Shares of IDEXX Laboratories, Inc. $IDXX

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.7% in the third quarter, HoldingsChannel.com reports. The firm owned 113,245 shares of the company’s stock after selling 60,082 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in IDEXX Laboratories were worth $72,351,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in IDXX. Bank of New York Mellon Corp boosted its position in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after buying an additional 884,808 shares during the period. Generation Investment Management LLP bought a new position in shares of IDEXX Laboratories during the second quarter valued at about $304,277,000. Norges Bank bought a new position in shares of IDEXX Laboratories during the second quarter valued at about $221,955,000. Schroder Investment Management Group boosted its holdings in shares of IDEXX Laboratories by 295.1% during the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after purchasing an additional 235,863 shares during the period. Finally, Montrusco Bolton Investments Inc. grew its stake in shares of IDEXX Laboratories by 50.3% in the second quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company’s stock worth $224,153,000 after purchasing an additional 143,641 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 4.1%

NASDAQ:IDXX opened at $686.02 on Wednesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The firm’s 50-day moving average price is $706.30 and its 200-day moving average price is $653.13. The company has a market capitalization of $54.78 billion, a PE ratio of 54.40, a P/E/G ratio of 3.83 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. IDEXX Laboratories’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on IDXX shares. Weiss Ratings raised IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, January 12th. Barclays began coverage on IDEXX Laboratories in a report on Monday, December 8th. They set an “overweight” rating and a $850.00 target price for the company. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday. BTIG Research raised their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, UBS Group boosted their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.